VistaGen Therapeutics Inc. (NASDAQ: VTGN) Committed to Developing New Generation Alternatives to Current Standard of Care for Anxiety Disorders
American Psychiatric Association poll reveals 62% of respondents have anxiety about COVID-19 Recent FDA Drug Safety Communication requires updated Boxed Warning for benzodiazepines commonly used to treat anxiety disorders VTGN is committed to developing and commercializing PH94B, a first-in-class pherine nasal spray with potential to go beyond the current standard of care for acute treatment of social anxiety disorder and other anxiety-related disorders Anxiety induced by the COVID-19 pandemic during the last year has been linked with surging use of benzodiazepines or “benzos,” a drug class commonly prescribed to treat anxiety and other disorders - a trend with potential to…